Valeant Pharmaceuticals Intl Inc (VRX) Earns Sector Perform Rating from Royal Bank Of Canada
Valeant Pharmaceuticals Intl Inc (TSE:VRX)‘s stock had its “sector perform” rating reaffirmed by investment analysts at Royal Bank Of Canada in a report released on Tuesday, StockTargetPrices.com reports.
A number of other research analysts have also recently weighed in on VRX. TD Securities reiterated a “buy” rating and set a C$38.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, August 10th. Scotiabank cut their price objective on shares of Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a “sector perform” rating on the stock in a research report on Monday, July 25th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of C$38.83.
Shares of Valeant Pharmaceuticals Intl (TSE:VRX) traded up 0.17% on Tuesday, reaching $36.09. 2,056,390 shares of the company were exchanged. The company’s market capitalization is $12.54 billion. The company’s 50-day moving average is $35.84 and its 200-day moving average is $39.40. Valeant Pharmaceuticals Intl has a 52 week low of $24.32 and a 52 week high of $325.49.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/valeant-pharmaceuticals-intl-inc-vrx-earns-sector-perform-rating-from-royal-bank-of-canada.html
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com’s FREE daily email newsletter.